Critical real‐world patient data observation of repurposable drugs from Alzheimer's disease drug development pipeline using Target Trial Emulation

Among the repurposable drugs tested in AD trials, real-world evidence supporting their effectiveness was limited (10%). Notably, bupropion, trazodone, venlafaxine, and zolpidem are potential candidates to reduce AD incidence. Further validation using independent patient data and clinical observations are highly warranted to establish potential clinical benefits of repurposable medicines in AD.